Replimune (REPL) Other Accumulated Expenses (2018 - 2021)
Replimune (REPL) posted Other Accumulated Expenses of $514000.0 for Q1 2021, down 0.96% sequentially from $519000.0 in Q4 2020, and up 69.64% YoY from $303000.0 in Q1 2020.
Replimune (REPL) Other Accumulated Expenses (2018 - 2021) Analysis & Trends
Replimune has reported Other Accumulated Expenses for 4 years, with the latest figure at $514000.0 in Q1 2021.
- Quarterly Other Accumulated Expenses rose 69.64% year-over-year to $514000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $514000.0 (up 69.64% YoY) and the FY2021 annual result came in at $514000.0, up 69.64% from the prior year.
- Other Accumulated Expenses slipped to $514000.0 in Q1 2021 per REPL's latest filing, from $519000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $974000.0 in Q3 2020 and troughed at $129000.0 in Q2 2018.
- A 4-year average of $379538.5 and a median of $303000.0 in 2020 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2019 and 2020: Other Accumulated Expenses grew 2.33% in 2019, then surged 335.61% in 2020.
- Over 4 years, Other Accumulated Expenses stood at $251000.0 in 2018, then surged by 37.45% to $345000.0 in 2019, then soared by 50.43% to $519000.0 in 2020, then dropped by 0.96% to $514000.0 in 2021.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $514000.0, $519000.0, and $974000.0 for Q1 2021, Q4 2020, and Q3 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 514,000.00 |
| Dec 31, 2020 | 519,000.00 |
| Sep 30, 2020 | 974,000.00 |
| Jun 30, 2020 | 575,000.00 |
| Mar 31, 2020 | 303,000.00 |
| Dec 31, 2019 | 345,000.00 |
| Sep 30, 2019 | 608,000.00 |
| Jun 30, 2019 | 132,000.00 |
| Mar 31, 2019 | 273,000.00 |
| Dec 31, 2018 | 251,000.00 |
| Sep 30, 2018 | 158,000.00 |
| Jun 30, 2018 | 129,000.00 |
| Mar 31, 2018 | 153,000.00 |